BOLT BIOTHERAPEUTICS

NetDania - New 12 months Low: BOLT BIOTHERAPEUTICS INC. - COMMON STOCK

20 May 2024 13:44:10 By NetDania Notify

NetDania - New 12 months Low: BOLT BIOTHERAPEUTICS INC. - COMMON STOCK

17 May 2024 09:47:43 By NetDania Notify

NetDania - New 12 months Low: BOLT BIOTHERAPEUTICS INC. - COMMON STOCK

16 May 2024 15:18:13 By NetDania Notify

NetDania - New 12 months Low: BOLT BIOTHERAPEUTICS INC. - COMMON STOCK

15 May 2024 10:16:14 By NetDania Notify

Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team

14 May 2024 16:05:00 By Nasdaq GlobeNewswire

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

21 Mar 2024 16:05:00 By Nasdaq GlobeNewswire

Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference

27 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®

05 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: BOLT BIOTHERAPEUTICS INC. - COMMON STOCK

30 Nov 2023 15:03:02 By NetDania Notify

NetDania - New 12 months Low: BOLT BIOTHERAPEUTICS INC. - COMMON STOCK

20 Nov 2023 15:31:57 By NetDania Notify

Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

09 Nov 2023 16:05:01 By Nasdaq GlobeNewswire

Bolt Biotherapeutics to Present at Stifel 2023 Healthcare Conference

07 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress

23 Oct 2023 10:30:00 By Nasdaq GlobeNewswire

Bolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer’s 2023 Annual Meeting

18 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers

17 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023

16 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers

28 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042

12 Sep 2023 08:05:25 By Nasdaq GlobeNewswire

Bolt Biotherapeutics to Participate in September Investor Conferences

05 Sep 2023 16:15:00 By Nasdaq GlobeNewswire

Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

07 Aug 2023 16:10:00 By Nasdaq GlobeNewswire